Takahashi, Nobuaki,Miura, Toru,Kitagawa, Yoshinori,Hirano, Aki
申请号：
NO20063197
公开号：
NO344608B1
申请日:
2006.07.10
申请国别(地区):
NO
年份:
2020
代理人:
摘要：
A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.
